[Form 4] Pharvaris N.V. Insider Trading Activity

Rhea-AI Filing Summary

Pharvaris N.V. Chief Early Development officer Anne Lesage reported a combination of stock option exercises and share sales in Pharvaris common stock. On April 22–23, 2026, she exercised 7,600 stock options and sold 14,700 common shares in open-market transactions at prices around $30 per share, as part of a Rule 10b5-1 trading plan.

Following these transactions, Lesage holds 56,450 Pharvaris shares directly and 156,869 shares indirectly through GrayMatters Consulting B.V. The exercised options carried strike prices of $8.05 and $2.59 and were originally subject to multi-year vesting schedules.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 11 txns

Insider Lesage Anne

Role Chief Early Development

Sold 14,700 shs ($442K)

Approx. gross sale proceeds $442K

Approx. exercise cost $58K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	100	$0.00	$0.00
Sale	Common Stock	100	$30.03	$3K
Exercise	Common Stock	100	$2.59	$259.00
Sale	Common Stock	100	$30.03	$3K
Exercise	Stock Option (Right to Buy)	500	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	7,000	$0.00	$0.00
Exercise	Common Stock	500	$2.59	$1K
Sale	Common Stock	500	$30.00	$15K
Exercise	Common Stock	7,000	$8.05	$56K
Sale	Common Stock	7,000	$30.0517	$210K
Sale	Common Stock	7,000	$30.0511	$210K

Holdings After Transaction: Stock Option (Right to Buy) — 128,872 contracts (Direct); Common Stock — 156,869 shares (Indirect, GrayMatters Consulting B.V.); Common Stock — 56,450 shares (Direct)

Footnotes (5)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13.
3. F3. These shares were sold in multiple transactions at prices ranging from $30.03 to $31.03.
4. F4. 25% of the option vested on January 1, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. F5. 25% of the option vested on February 5, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 12:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lesage Anne

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Early Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/22/2026		M(1)		500	A	$2.59	56,950	D
Common Stock	04/22/2026		S(1)		500	D	$30	56,450	D
Common Stock	04/22/2026		M(1)		7,000	A	$8.05	63,450	D
Common Stock	04/22/2026		S(1)		7,000	D	$30.0517(2)	56,450	D
Common Stock	04/22/2026		S		7,000	D	$30.0511(2)	156,969	I	GrayMatters Consulting B.V.
Common Stock	04/23/2026		S		100	D	$30.03	156,869	I	GrayMatters Consulting B.V.
Common Stock	04/23/2026		M(1)		100	A	$2.59	56,550	D
Common Stock	04/23/2026		S(1)		100	D	$30.03(3)	56,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	04/22/2026		M(1)			500	(4)	01/01/2030	Common Stock	500	$0	15,972	D
Stock Option (Right to Buy)	$8.05	04/22/2026		M(1)			7,000	(5)	02/05/2031	Common Stock	7,000	$0	113,000	D
Stock Option (Right to Buy)	$2.59	04/23/2026		M(1)			100	(4)	01/01/2030	Common Stock	100	$0	15,872	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13.

3. These shares were sold in multiple transactions at prices ranging from $30.03 to $31.03.

4. 25% of the option vested on January 1, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on February 5, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)